Safety and Tolerability of Metronidazole Gel 1.3%

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-12

Study Completion Date

2016-10-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multicenter, open-label study to evaluate safety and tolerability of Metronidazole Vaginal Gel in females 12 to \<18 years for the treatment of bacterial vaginosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multi-Center Study of New Medications to Treat Vaginal Infections

NCT02308033

Vaginal Infection

COMPLETED PHASE3

Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis

NCT01020396

Bacterial Vaginosis

COMPLETED PHASE1/PHASE2

Multi-Center Study of New Medications to Treat Vaginal Infections

NCT02308046

Vaginal Infection

COMPLETED PHASE3

Multi-Center Study of New Medications to Treat Vaginal Infections

NCT02308007

Vaginal Infection

COMPLETED PHASE3

Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis

NCT02709005

Bacterial Vaginosis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A multicenter, open-label study to evaluate safety and tolerability of Metronidazole Vaginal Gel 1.3% when administered as a single dose in adolescent females (aged 12 to \<18 years) for the treatment of bacterial vaginosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaginosis, Bacterial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metronidazole Gel

Metronidazole Vaginal Gel

Group Type EXPERIMENTAL

Metronidazole Gel

Intervention Type DRUG

Metronidazole Vaginal Gel 1.3% administered via applicator

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metronidazole Gel

Metronidazole Vaginal Gel 1.3% administered via applicator

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Metro Gel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provide written assent and parent/legal guardian informed consent and authorization to disclose protected health information.
* Post-menarcheal, adolescent female, 12 to \<18 years of age at time of Screening/Baseline Visit (Day 1).
* In good general health at Screening visit with no known medical conditions that, in the Investigator's opinion, may interfere with study participation.
* Has negative urine pregnancy test result prior to study treatment initiation.
* Has clinical diagnosis of bacterial vaginosis.
* Agree to abstain from sexual intravaginal intercourse for study duration.
* Willing to avoid alcohol ingestion for 24 hours after administration of test article.
* Agree to refrain from use of intravaginal products for duration of study (e.g. lubricated condoms, tampons, diaphragms, spermicides, feminine deodorant sprays, douches). Intravaginal Uterine Device (IUD) use is acceptable as long as it has been in place for 30 days prior to study enrollment.
* Willing and able to participate in study, make required visits to the study center, and comply with all study requirements including concomitant medication and other treatment restrictions.

Exclusion Criteria

* Pregnant, lactating, or planning to become pregnant during study period.
* Currently menstruating or anticipate onset of menses during first 9 days of the study.
* Experience a clinically important medical event with 90 days of Screening/Baseline Visit (Day 1).
* Evidence of other infectious causes of vulvovaginal infection or condition that in the Investigator's opinion would confound the interpretation of the study results.
* Severe symptoms of dysuria and/or pruritus, burning or irritation in vulvovaginal area.
* Received systemic or intravaginal antifungal, antibacterial or antiparasitic drugs within 14 days of Screening/Baseline visit (Day 1). Antiviral therapies (non-intravaginal) are acceptable.
* Has taken disulfiram or systemic corticosteroids (oral or injected) within 14 days of Screening/Baseline Visit (Day 1).
* Had sexual intravaginal intercourse within 24 hours of Screening/Baseline (Day 1).
* Demonstrated previous hypersensitivity to metronidazole, either orally or topically administered, or any form of parabens or benzyl alcohol.
* Known primary or secondary immunodeficiency condition/syndrome.
* Being treated or planning to be treated during the study period for cervical intraepithelial neoplasia (CIN) or cervical carcinoma.
* Using anticoagulation therapy with Coumadin (warfarin).
* Previously treated with test article under this protocol.
* Participate in an experimental drug/device trial within the last 30 days before Screening/Baseline Visit (Day 1).
* Is judged by the Investigator to be unsuitable for any reason.

Minimum Eligible Age

12 Years

Maximum Eligible Age

17 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No